|
|
|
|
||
Re: Competitor ? Different type of stem cell, but similar treatment protocol. MESO, however, only has a Phase 1 safety study while ATHX has completed Phase II. Still waiting for BARDA to cough up some cash. ATHX can't afford to offer MultiStem on a compassionate basis (for free). |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
1741 | Re: Competitor ? | tekbull | 2 | 4/6/2020 3:21:01 PM |